Independent
Tenure on this board
8.9 yrs
Meeting calendar
HRMY · Annual meeting · Thursday, May 14, 2026
Harmony Biosciences Holdings Inc
4 nominees · 3 ballot items.
Election of four Class III directors; Ratification of Deloitte & Touche LLP as independent auditor; Non-binding advisory vote to approve named executive officer compensation (say-on-pay).
Market cap
$2.0B
1Y TSR
+1.7%
Board grade
C
Record date
Mar 17, 2026
Filing
DEF 14A
Meeting concluded · May 14, 2026
Follow how the vote landed and what changed on Harmony Biosciences Holdings Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect four Class III directors (Andreas Wicki, Geno Germano, Troy Ignelzi, Ron Philip) to serve until the 2029 annual meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
More detail
This management proposal asks shareholders to ratify the audit committee’s appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending Dec 31, 2026. Management seeks ratification both as a governance practice and to reassure continuity in auditing — Deloitte has served since 2017 — while reserving the audit committee’s discretion to replace the firm if warranted. The proposal is routine and typically passes; ratification requires a simple majority of votes cast. The board recommends a FOR vote, citing Deloitte’s tenure and the audit committee’s oversight of fees, independence and pre-approval policies; the proxy statement discloses audit and tax fees for 2025 and 2024 and affirms audit committee pre-approval procedures.
- 3
Advisory Vote on Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of named executive officers as disclosed in the proxy statement.
More detail
This management proposal asks shareholders to cast a non-binding advisory vote approving the company’s named executive officer compensation as disclosed under Item 402. Management frames its compensation program as performance-based, linking pay to WAKIX revenue growth, clinical milestones, corporate transactions, financial health and talent/culture objectives, and emphasizes long-term equity incentives to align management and shareholder interests. The Board will consider the outcome when setting future compensation. The recommendation is FOR, and the materials provide detailed CD&A, pay-versus-performance, and compensation governance practices. The proposal is advisory and requires a majority of votes cast to pass.
Director elections
Nominees on the ballot4
Independent
Tenure on this board
0.2 yrs
Also a director at
Precision Biosciences Inc (DTIL)Entera Bio Ltd (ENTX)
Independent
Tenure on this board
0.3 yrs
Also a director at
Contineum Therapeutics Inc (CTNM)
Independent
Tenure on this board
1.3 yrs
Also a director at
Avalo Therapeutics Inc (AVTX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.6% | 4,372,656 | $122M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 2,714,353 | $76M |
| 3 | AMERICAN CENTURY COMPANIES INC | 3.6% | 2,105,179 | $59M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 2,102,315 | $59M |
| 5 | LSV ASSET MANAGEMENT | 3.5% | 2,025,143 | $57M |
| 6 | SG Americas Securities, LLC | 3.5% | 2,018,174 | $57M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 3.4% | 1,945,680 | $54M |
| 8 | STATE STREET CORP | 3.1% | 1,784,362 | $50M |
| 9 | FMR LLC | 2.9% | 1,688,568 | $47M |
| 10 | ARMISTICE CAPITAL, LLC | 2.8% | 1,624,000 | $45M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Harmony Biosciences Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Reference
Frequently asked questions
- When is the Harmony Biosciences Holdings Inc 2026 annual meeting?
- Harmony Biosciences Holdings Inc (HRMY) holds its 2026 annual shareholder meeting on Thursday, May 14, 2026.
- What is the record date for the Harmony Biosciences Holdings Inc 2026 meeting?
- The record date for the Harmony Biosciences Holdings Inc 2026 meeting is Tuesday, March 17, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Harmony Biosciences Holdings Inc's 2026 meeting?
- The board is presenting 4 director nominees at the Harmony Biosciences Holdings Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Harmony Biosciences Holdings Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Harmony Biosciences Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.